Company Profile

SomaLogic, Inc. is a commercial-stage proteomics company. The Company has built an integrated proteomics platform, which offers throughput proteomics analysis with broad proteome coverage. It develops slow off-rate modified aptamers (SOMAmers), which are modified nucleic acid-based protein binding reagents that are specific for their cognate protein. It offers SomaScan services, which provide multiplex protein detection and quantification of protein levels in complex biological samples. Its products include SomaScan Assay, SomaScan Certified Sites, SomaSignal Tests and SOMAmer Reagents. SomaScan Assay is utilized for Research Use Only (RUO) applications. Its SomaScan Assay measures approximately 7,000 protein target measurements in a single sample. Its SOMAmer reagents are proprietary modified aptamers, which are short, synthetic single-stranded DNA (ssDNA) sequences developed to bind specific protein targets with high affinity and specificity across the proteome.

Employees

451

Sector

Biotechnology & Medical Research

More about the company

24/06/25	Illumina, Inc. entered into an agreement to acquire SomaLogic, Inc. from Standard BioTools Inc. for approximately $430 million.	CI
10/01/24	Standard BioTools Inc.(NasdaqGM:SLGC) dropped from S&P Global BMI Index	CI
10/01/24	Standard BioTools Inc.(NasdaqGM:SLGC) dropped from S&P TMI Index	CI
08/01/24	Somalogic, Inc. Provides Revenue Guidance for Fourth Quarter and Full Year 2023	CI
06/01/24	Declaration of Voting Results by SomaLogic Inc	CI
06/01/24	Declaration of Voting Results by SomaLogic Inc	CI
06/01/24	Declaration of Voting Results by SomaLogic Inc	CI
06/01/24	Declaration of Voting Results by SomaLogic Inc	CI
06/01/24	Declaration of Voting Results by SomaLogic Inc	CI
05/01/24	Standard BioTools Says Merger With SomaLogic Completed	MT
05/01/24	SomaLogic, Standard BioTools Receive Shareholder Approvals for Pending Merger	MT
05/01/24	SomaLogic, Inc.(NasdaqGM:SLGC) dropped from NASDAQ Composite Index	CI
05/01/24	Madryn Asset Addresses SomaLogic?s Failure to Obtain Requisite Shareholder Support for the Proposed Merger with Standard BioTools	CI

30/12/23	Glass Lewis and ISS Recommends SomaLogic Stockholders to Vote for Proposed Merger	CI
30/12/23	Glass Lewis and ISS Recommends SomaLogic Stockholders to Vote for Proposed Merger	CI
30/12/23	Glass Lewis and ISS Recommends SomaLogic Stockholders to Vote for Proposed Merger	CI
30/12/23	Glass Lewis and Institutional Shareholder Services Support SomaLogic	CI
05/10/23	Jefferies Downgrades SomaLogic to Hold From Buy, Adjusts Price Target to $2.30 From $3.50	MT

05/01/24	Standard BioTools Stockholders Approve Merger with SomaLogic	AQ
05/01/24	SomaLogic Stockholders Vote to Approve Standard BioTools Transaction at Special Meeting	PR
05/01/24	Madryn Asset Management Demands SomaLogic’s Board Address Repeated, Unprecedented Adjournments of Tainted Special Meeting	BU
05/01/24	Madryn Asset Management Addresses SomaLogic’s Apparent Failure to Obtain Requisite Shareholder Support for the Proposed Merger with Standard BioTools	BU
03/01/24	Proxy Advisory Firm Egan-Jones Recommends SomaLogic Shareholders Vote Against Proposed Merger with Standard BioTools	BU

Director	Title	Age	Since
Jeffrey Black BRD	Director/Board Member	57	05/01/2024
Hanjoon Kim BRD	Director/Board Member	55	05/01/2024

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
STANDARD BIOTOOLS INC.	-4.55%	-17.00%	-	-	396M
LONZA GROUP AG	-0.72%	-4.60%	-12.29%	-7.25%	42.78B
BEONE MEDICINES AG	-0.44%	-5.67%	+9.59%	+20.39%	31.5B
CELLTRION, INC.	-0.24%	-3.29%	+14.84%	+48.42%	29.99B
IQVIA HOLDINGS INC.	+1.10%	-5.60%	-11.05%	-15.65%	27.65B
REVOLUTION MEDICINES, INC.	-0.22%	-3.60%	+142.48%	+312.79%	18.8B
ASCENDIS PHARMA A/S	-1.32%	-6.10%	+47.72%	+108.24%	13.87B
MEDPACE HOLDINGS, INC.	+1.48%	-4.29%	+38.61%	+153.12%	12.78B
EUROFINS SCIENTIFIC SE	-0.29%	-4.80%	+24.93%	+2.16%	12.39B
IONIS PHARMACEUTICALS, INC.	-1.59%	-3.85%	+115.99%	+108.22%	11.76B
Average	-0.68%	-4.20%	+41.20%	+81.16%	22.39B
Weighted average by Cap.	-0.24%	-4.07%	+26.91%	+59.50%

Standard BioTools Inc. Stock

Equities

SLGC

US83444K1051

Biotechnology & Medical Research

Latest news: Standard BioTools Inc.

Analysts' recommendations: Standard BioTools Inc.

Press Releases: Standard BioTools Inc.

Quotes and Performance

Managers and Directors: Standard BioTools Inc.

ETFs: Standard BioTools Inc.

Other Biotechnology & Medical Research

Company Profile